Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 351

1.

Advances in management of Guillain-Barré syndrome.

Doets AY, Jacobs BC, van Doorn PA.

Curr Opin Neurol. 2018 Jul 31. doi: 10.1097/WCO.0000000000000602. [Epub ahead of print]

PMID:
30074496
2.

A design framework and exemplar metrics for FAIRness.

Wilkinson MD, Sansone SA, Schultes E, Doorn P, Bonino da Silva Santos LO, Dumontier M.

Sci Data. 2018 Jun 26;5:180118. doi: 10.1038/sdata.2018.118. No abstract available.

3.

Factor V Has Anticoagulant Activity in Plasma in the Presence of TFPIα: Difference between FV1 and FV2.

van Doorn P, Rosing J, Duckers C, Hackeng TM, Simioni P, Castoldi E.

Thromb Haemost. 2018 Jul;118(7):1194-1202. doi: 10.1055/s-0038-1656549. Epub 2018 Jun 4.

PMID:
29864781
4.

Enzyme replacement therapy reduces the risk for wheelchair dependency in adult Pompe patients.

van der Meijden JC, Kruijshaar ME, Rizopoulos D, van Doorn PA, van der Beek NAME, van der Ploeg AT.

Orphanet J Rare Dis. 2018 May 22;13(1):82. doi: 10.1186/s13023-018-0824-4.

5.

A randomised, multi-centre phase III study of 3 different doses of intravenous immunoglobulin 10% in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ProCID trial): Study design and protocol.

Cornblath DR, Hartung HP, Katzberg HD, Merkies ISJ, van Doorn PA.

J Peripher Nerv Syst. 2018 Jun;23(2):108-114. doi: 10.1111/jns.12267. Epub 2018 Apr 26.

6.

Imaging of respiratory muscles in neuromuscular disease: A review.

Harlaar L, Ciet P, van der Ploeg AT, Brusse E, van der Beek NAME, Wielopolski PA, de Bruijne M, Tiddens HAWM, van Doorn PA.

Neuromuscul Disord. 2018 Mar;28(3):246-256. doi: 10.1016/j.nmd.2017.11.010. Epub 2017 Nov 24. Review.

PMID:
29398294
7.

Protocol of a dose response trial of IV immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy (DRIP study).

Kuitwaard K, Fokkink WR, Brusse E, Vrancken AFJE, Eftimov F, Notermans NC, van der Kooi AJ, Merkies ISJ, Jacobs BC, van Doorn PA.

J Peripher Nerv Syst. 2018 Mar;23(1):5-10. doi: 10.1111/jns.12244. Epub 2017 Nov 21.

PMID:
29119642
8.

Long-term benefit of enzyme replacement therapy in Pompe disease: A 5-year prospective study.

Kuperus E, Kruijshaar ME, Wens SCA, de Vries JM, Favejee MM, van der Meijden JC, Rizopoulos D, Brusse E, van Doorn PA, van der Ploeg AT, van der Beek NAME.

Neurology. 2017 Dec 5;89(23):2365-2373. doi: 10.1212/WNL.0000000000004711. Epub 2017 Nov 8.

PMID:
29117951
9.

Maintenance IV immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy.

Kuitwaard K, Fokkink WR, Brusse E, Vrancken AFJE, Eftimov F, Notermans NC, van der Kooi AJ, Merkies ISJ, Jacobs BC, van Doorn PA.

J Peripher Nerv Syst. 2017 Dec;22(4):425-432. doi: 10.1111/jns.12242. Epub 2017 Nov 21. Review.

PMID:
29092099
10.

Prediction of disease progression in Miller Fisher and overlap syndromes.

Verboon C, van Berghem H, van Doorn PA, Ruts L, Jacobs BC.

J Peripher Nerv Syst. 2017 Dec;22(4):446-450. doi: 10.1111/jns.12238. Epub 2017 Nov 15.

PMID:
29065229
11.

Small volume plasma exchange for Guillain-Barré syndrome in resource poor settings: a safety and feasibility study.

Islam MB, Islam Z, Rahman S, Endtz HP, Vos MC, van der Jagt M, van Doorn PA, Jacobs BC, Mohammad QD.

Pilot Feasibility Stud. 2017 Sep 29;3:40. doi: 10.1186/s40814-017-0185-0. eCollection 2017.

12.

The reduction of intraepidermal P2X3 nerve fiber density correlates with behavioral hyperalgesia in a rat model of nerve injury-induced pain.

Bechakra M, Schüttenhelm BN, Pederzani T, van Doorn PA, de Zeeuw CI, Jongen JLM.

J Comp Neurol. 2017 Dec 1;525(17):3757-3768. doi: 10.1002/cne.24302. Epub 2017 Aug 30.

PMID:
28815599
13.

Response to Herbert et al.

de Vries JM, Kuperus E, Hoogeveen-Westerveld M, Kroos MA, Wens SCA, Stok M, van der Beek NAME, Kruijshaar ME, Rizopoulos D, van Doorn PA, van der Ploeg AT, Pijnappel WWMP.

Genet Med. 2017 Nov;19(11):1283-1284. doi: 10.1038/gim.2017.49. Epub 2017 Jun 29. No abstract available.

PMID:
28661488
14.

Polyneuropathy relates to impairment in daily activities, worse gait, and fall-related injuries.

Hanewinckel R, Drenthen J, Verlinden VJA, Darweesh SKL, van der Geest JN, Hofman A, van Doorn PA, Ikram MA.

Neurology. 2017 Jul 4;89(1):76-83. doi: 10.1212/WNL.0000000000004067. Epub 2017 May 31.

PMID:
28566544
15.

Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy.

Mahdi-Rogers M, Brassington R, Gunn AA, van Doorn PA, Hughes RA.

Cochrane Database Syst Rev. 2017 May 8;5:CD003280. doi: 10.1002/14651858.CD003280.pub5. Review.

PMID:
28481421
16.

European consensus for starting and stopping enzyme replacement therapy in adult patients with Pompe disease: a 10-year experience.

van der Ploeg AT, Kruijshaar ME, Toscano A, Laforêt P, Angelini C, Lachmann RH, Pascual Pascual SI, Roberts M, Rösler K, Stulnig T, van Doorn PA, Van den Bergh PYK, Vissing J, Schoser B; European Pompe Consortium.

Eur J Neurol. 2017 Jun;24(6):768-e31. doi: 10.1111/ene.13285. Epub 2017 May 6. Review.

PMID:
28477382
17.

High body mass and kidney dysfunction relate to worse nerve function, even in adults without neuropathy.

Hanewinckel R, Ikram MA, Franco OH, Hofman A, Drenthen J, van Doorn PA.

J Peripher Nerv Syst. 2017 Jun;22(2):112-120. doi: 10.1111/jns.12211.

PMID:
28429469
18.

International Guillain-Barré Syndrome Outcome Study: protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome in Guillain-Barré syndrome.

Jacobs BC, van den Berg B, Verboon C, Chavada G, Cornblath DR, Gorson KC, Harbo T, Hartung HP, Hughes RAC, Kusunoki S, van Doorn PA, Willison HJ; IGOS Consortium.

J Peripher Nerv Syst. 2017 Jun;22(2):68-76. doi: 10.1111/jns.12209.

PMID:
28406555
19.

Pharmacokinetics and Pharmacodynamics of Intravenous Immunoglobulin G Maintenance Therapy in Chronic Immune-mediated Neuropathies.

Fokkink W, Koch B, Ramakers C, van Doorn PA, van Gelder T, Jacobs BC.

Clin Pharmacol Ther. 2017 Oct;102(4):709-716. doi: 10.1002/cpt.693. Epub 2017 Jun 5.

PMID:
28378901
20.

Guillain-Barré syndrome: surveillance and cost of treatment strategies - Authors' reply.

Willison HJ, Jacobs BC, van Doorn PA.

Lancet. 2017 Jan 21;389(10066):253-254. doi: 10.1016/S0140-6736(17)30055-7. Epub 2017 Jan 20. No abstract available.

PMID:
28118915
21.

Commentary.

Pijnappel WW, van Doorn PA, van der Ploeg AT.

Clin Chem. 2017 Jan;63(1):48. doi: 10.1373/clinchem.2016.265280. No abstract available.

22.

Association of Albumin Levels With Outcome in Intravenous Immunoglobulin-Treated Guillain-Barré Syndrome.

Fokkink WR, Walgaard C, Kuitwaard K, Tio-Gillen AP, van Doorn PA, Jacobs BC.

JAMA Neurol. 2017 Feb 1;74(2):189-196. doi: 10.1001/jamaneurol.2016.4480.

PMID:
28027337
23.

Treatment dilemmas in Guillain-Barré syndrome.

Verboon C, van Doorn PA, Jacobs BC.

J Neurol Neurosurg Psychiatry. 2017 Apr;88(4):346-352. doi: 10.1136/jnnp-2016-314862. Epub 2016 Nov 11. Review.

PMID:
27837102
24.

Inhibition of complement in Guillain-Barré syndrome: the ICA-GBS study.

Davidson AI, Halstead SK, Goodfellow JA, Chavada G, Mallik A, Overell J, Lunn MP, McConnachie A, van Doorn P, Willison HJ.

J Peripher Nerv Syst. 2017 Mar;22(1):4-12. doi: 10.1111/jns.12194.

PMID:
27801990
25.

The C-terminus of tissue factor pathway inhibitor-α inhibits factor V activation by protecting the Arg1545 cleavage site.

van Doorn P, Rosing J, Wielders SJ, Hackeng TM, Castoldi E.

J Thromb Haemost. 2017 Jan;15(1):140-149. doi: 10.1111/jth.13559. Epub 2016 Dec 3.

PMID:
27801970
26.

Corticosteroids for Guillain-Barré syndrome.

Hughes RA, Brassington R, Gunn AA, van Doorn PA.

Cochrane Database Syst Rev. 2016 Oct 24;10:CD001446. Review.

PMID:
27775812
27.

Prevalence of polyneuropathy in the general middle-aged and elderly population.

Hanewinckel R, Drenthen J, van Oijen M, Hofman A, van Doorn PA, Ikram MA.

Neurology. 2016 Nov 1;87(18):1892-1898. Epub 2016 Sep 28.

PMID:
27683845
28.

Atypical Porcine Pestivirus: A Possible Cause of Congenital Tremor Type A-II in Newborn Piglets.

de Groof A, Deijs M, Guelen L, van Grinsven L, van Os-Galdos L, Vogels W, Derks C, Cruijsen T, Geurts V, Vrijenhoek M, Suijskens J, van Doorn P, van Leengoed L, Schrier C, van der Hoek L.

Viruses. 2016 Oct 4;8(10). pii: E271.

29.

Metabolic syndrome is related to polyneuropathy and impaired peripheral nerve function: a prospective population-based cohort study.

Hanewinckel R, Drenthen J, Ligthart S, Dehghan A, Franco OH, Hofman A, Ikram MA, van Doorn PA.

J Neurol Neurosurg Psychiatry. 2016 Dec;87(12):1336-1342. doi: 10.1136/jnnp-2016-314171. Epub 2016 Sep 21.

PMID:
27656045
30.

Peripheral neuropathies.

Hanewinckel R, Ikram MA, Van Doorn PA.

Handb Clin Neurol. 2016;138:263-82. doi: 10.1016/B978-0-12-802973-2.00015-X. Review.

PMID:
27637963
31.

Tracheostomy or Not: Prediction of Prolonged Mechanical Ventilation in Guillain-Barré Syndrome.

Walgaard C, Lingsma HF, van Doorn PA, van der Jagt M, Steyerberg EW, Jacobs BC.

Neurocrit Care. 2017 Feb;26(1):6-13. doi: 10.1007/s12028-016-0311-5.

32.

Quantification of Diaphragm Mechanics in Pompe Disease Using Dynamic 3D MRI.

Mogalle K, Perez-Rovira A, Ciet P, Wens SC, van Doorn PA, Tiddens HA, van der Ploeg AT, de Bruijne M.

PLoS One. 2016 Jul 8;11(7):e0158912. doi: 10.1371/journal.pone.0158912. eCollection 2016.

33.

Neonatal Fc receptor promoter gene polymorphism does not predict pharmacokinetics of IVIg or the clinical course of GBS.

Fokkink WJ, Haarman AE, Tio-Gillen AP, van Rijs W, Huizinga R, van Doorn PA, Jacobs BC.

Ann Clin Transl Neurol. 2016 May 17;3(7):547-51. doi: 10.1002/acn3.307. eCollection 2016 Jul. Erratum in: Ann Clin Transl Neurol. 2017 Jan 09;4(1):71.

34.

Pompe disease in adulthood: effects of antibody formation on enzyme replacement therapy.

de Vries JM, Kuperus E, Hoogeveen-Westerveld M, Kroos MA, Wens SC, Stok M, van der Beek NA, Kruijshaar ME, Rizopoulos D, van Doorn PA, van der Ploeg AT, Pijnappel WW.

Genet Med. 2017 Jan;19(1):90-97. doi: 10.1038/gim.2016.70. Epub 2016 Jun 30.

PMID:
27362911
35.

Neuronal endocytosis of anti-ganglioside antibodies: implications for Guillain-Barré syndrome.

van Doorn PA, Jacobs BC.

Brain. 2016 Jun;139(Pt 6):1622-5. doi: 10.1093/brain/aww078. No abstract available.

PMID:
27234059
36.

[Guillain-Barré syndrome following infection with the Zika virus].

van den Berg B, van den Beukel JC, Alsma J, van der Eijk AA, Ruts L, van Doorn PA, Jacobs BC, Simon CC.

Ned Tijdschr Geneeskd. 2016;160:D155. Dutch.

PMID:
27229696
37.

The epidemiology of neuromuscular disorders: Age at onset and gender in the Netherlands.

Deenen JC, van Doorn PA, Faber CG, van der Kooi AJ, Kuks JB, Notermans NC, Visser LH, Horlings CG, Verschuuren JJ, Verbeek AL, van Engelen BG.

Neuromuscul Disord. 2016 Jul;26(7):447-52. doi: 10.1016/j.nmd.2016.04.011. Epub 2016 Apr 21.

PMID:
27212207
38.

Minutes of the European POmpe Consortium (EPOC) Meeting March 27 to 28, 2015, Munich, Germany.

Schoser B, Laforêt P, Kruijshaar ME, Toscano A, van Doorn PA, van der Ploeg AT; European POmpe Consortium (EPOC).

Acta Myol. 2015 Dec;34(2-3):141-3. No abstract available.

39.

Correlation of the patient's reported outcome Inflammatory-RODS with an objective metric in immune-mediated neuropathies.

Draak TH, Gorson KC, Vanhoutte EK, van Nes SI, van Doorn PA, Cornblath DR, van den Berg LH, Faber CG, Merkies IS; PeriNomS Study Group.

Eur J Neurol. 2016 Jul;23(7):1248-53. doi: 10.1111/ene.13025. Epub 2016 Apr 29.

PMID:
27129110
40.

Assessment scales for the diagnosis of polyneuropathy.

Hanewinckel R, Ikram MA, van Doorn PA.

J Peripher Nerv Syst. 2016 Jun;21(2):61-73. doi: 10.1111/jns.12170. Review.

PMID:
26968746
41.

Does ability to walk reflect general functionality in inflammatory neuropathies?

Draak TH, Gorson KC, Vanhoutte EK, van Nes SI, van Doorn PA, Cornblath DR, van den Berg LH, Faber CG, Merkies IS; PeriNomS Study Group.

J Peripher Nerv Syst. 2016 Jun;21(2):74-81. doi: 10.1111/jns.12167.

PMID:
26968437
42.

Guillain-Barré syndrome.

Willison HJ, Jacobs BC, van Doorn PA.

Lancet. 2016 Aug 13;388(10045):717-27. doi: 10.1016/S0140-6736(16)00339-1. Epub 2016 Mar 2. Review.

PMID:
26948435
43.

Cognitive decline in classic infantile Pompe disease: An underacknowledged challenge.

Ebbink BJ, Poelman E, Plug I, Lequin MH, van Doorn PA, Aarsen FK, van der Ploeg AT, van den Hout JM.

Neurology. 2016 Mar 29;86(13):1260-1. doi: 10.1212/WNL.0000000000002523. Epub 2016 Mar 4. No abstract available.

PMID:
26944269
44.

Hospital Admissions, Transfers and Costs of Guillain-Barré Syndrome.

van Leeuwen N, Lingsma HF, Vanrolleghem AM, Sturkenboom MC, van Doorn PA, Steyerberg EW, Jacobs BC.

PLoS One. 2016 Feb 9;11(2):e0143837. doi: 10.1371/journal.pone.0143837. eCollection 2016.

45.

Elevated Plasma Cardiac Troponin T Levels Caused by Skeletal Muscle Damage in Pompe Disease.

Wens SC, Schaaf GJ, Michels M, Kruijshaar ME, van Gestel TJ, In 't Groen S, Pijnenburg J, Dekkers DH, Demmers JA, Verdijk LB, Brusse E, van Schaik RH, van der Ploeg AT, van Doorn PA, Pijnappel WW.

Circ Cardiovasc Genet. 2016 Feb;9(1):6-13. doi: 10.1161/CIRCGENETICS.115.001322. Epub 2016 Jan 19.

PMID:
26787432
46.

The epidemiology and risk factors of chronic polyneuropathy.

Hanewinckel R, van Oijen M, Ikram MA, van Doorn PA.

Eur J Epidemiol. 2016 Jan;31(1):5-20. doi: 10.1007/s10654-015-0094-6. Epub 2015 Dec 23. Review.

47.

Gait characteristics in older adults with diabetes and impaired fasting glucose: The Rotterdam Study.

Maksimovic A, Hanewinckel R, Verlinden VJ, Ligthart S, Hofman A, Franco OH, van Doorn PA, Tiemeier H, Dehghan A, Ikram MA.

J Diabetes Complications. 2016 Jan-Feb;30(1):61-6. doi: 10.1016/j.jdiacomp.2015.10.006. Epub 2015 Oct 20.

48.

Quality of life and participation in daily life of adults with Pompe disease receiving enzyme replacement therapy: 10 years of international follow-up.

Güngör D, Kruijshaar ME, Plug I, Rizopoulos D, Kanters TA, Wens SC, Reuser AJ, van Doorn PA, van der Ploeg AT.

J Inherit Metab Dis. 2016 Mar;39(2):253-60. doi: 10.1007/s10545-015-9889-6. Epub 2015 Nov 3.

49.

Lack of robust satellite cell activation and muscle regeneration during the progression of Pompe disease.

Schaaf GJ, van Gestel TJ, Brusse E, Verdijk RM, de Coo IF, van Doorn PA, van der Ploeg AT, Pijnappel WW.

Acta Neuropathol Commun. 2015 Oct 28;3:65. doi: 10.1186/s40478-015-0243-x.

50.

Rasch-built Overall Disability Scale for Multifocal motor neuropathy (MMN-RODS(©) ).

Vanhoutte EK, Faber CG, van Nes SI, Cats EA, Van der Pol WL, Gorson KC, van Doorn PA, Cornblath DR, van den Berg LH, Merkies IS; PeriNomS Study Group.

J Peripher Nerv Syst. 2015 Sep;20(3):296-305. doi: 10.1111/jns.12141. Erratum in: J Peripher Nerv Syst. 2016 Mar;21(1):55.

PMID:
26329270

Supplemental Content

Support Center